anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Circadian rhythm is an essential component of biology that organizes the internal synchrony of the organism in response to the environment. Aging significantly impacts circadian rhythm and is also associated with specific sleep complaints in mammals, including earlier awakening and decreased sleep consolidation at the end of the night. However, the regulation mechanism of aging on the circadian rhythm is far from clear. To further understand the impact of aging, we use an existing mathematical model of circadian rhythm combined with the aging system to explore the effects of aging on circadian rhythm and two kinds of sleep disorders, familial late sleep syndrome (FASPS) and delayed sleep syndrome (DSPS). We get a few intriguing findings from numerical simulations. Aging weakens rhythmicity by reducing the amplitude of circadian rhythm. Aging exacerbates the sleep pattern of being early to bed and early to rise by shortening the period of circadian rhythm and advancing the entrainment phase. Aging reduces the ability of the circadian rhythm to respond to light. The elderly need stronger light to get entrainment with the environmental light cycle. It is more difficult for the elderly to recover from disturbed light. Especially elderly people take a longer time to overcome jet lag. Aging worsens the "morningness" of FASPS disorder patients and improves the symptoms of DSPS disorder patients. This study helps to better understand the impacts of aging on circadian rhythm and sleep disorders and provides theoretical support for the treatment of circadian disorders in the elderly.
Student Co-PI will manage this Instagram account created for the study. Although the student is a Kinesiology student and works within the health field, she will not disclose this information on the account. Instead, she will present herself as a general college student. By withholding her major and career aspirations, we hope to get unbiased feedback on what participants think about the content being presented. The content presented will be identical to study arm #3.
The present invention relates to a medicine for treating oral ulcer, which is characterized in that No. 33 alpha-hemolytic streptococcus strains are carried by a roundtrip outer space vehicle, DNA double strands in a microbial cell are broken under the special condition of the outer space, and the repair of injured DNA is inhibited in a microgravity environment and a high vacuum environment, so that the hereditary properties of the strains are mutated; strains with positive mutation and stable hereditary properties are preferably selected, bred and fermented to be produced into a biochemical preparation for treating oral ulcer. The strains are preserved in China General Microbiological Culture Collection Center and have a serial number of CGMCCNO. 1082. The biochemical preparation for treating oral ulcer is a film adhesion agent, and 1000 ml of the biochemical preparation contains 0.25g to 5.0g of mannon peptide produced by using the strains mutated in the outer space. The medicine for treating oral ulcer adopts an alpha-mannon peptide oral ulcer film to treat oral ulcer and has the characteristics of rapid ulcer healing after treatment, low recurrence rate, reliable therapeutic effect superior to the conventional therapy, no toxic action, little side effect and high effective rate.
BACKGROUND: Multimorbidity, known as the co-occurrence of at least two chronic conditions, has become of increasing concern in the current context of ageing populations, though it affects all ages. Early life risk factors of multimorbidity include adverse childhood experiences (ACEs), particularly associated with psychological conditions and weight problems. Few studies have considered related mechanisms and focus on old age participants. We are interested in estimating, from young adulthood, the risk of overweight-depression comorbidity related to ACEs while adjusting for early life confounders and intermediate variables.
METHODS: We used data from the 1958 National Child Development Study, a prospective birth cohort study (N = 18 558). A four-category outcome (no condition, overweight only, depression only and, overweight-depression comorbidity) was constructed at 23, 33, and 42 years. Multinomial logistic regression models adjusting for intermediate variables co-occurring with this outcome were created. ACEs and sex interaction on comorbidity risk was tested.
RESULTS: In our study sample (N = 7762), we found that ACEs were associated with overweight-depression comorbidity risk throughout adulthood (RRR [95% CI] at 23y = 3.80 [2.10-6.88]) though less overtime. Comorbidity risk was larger than risk of separate conditions. Intermediate variables explained part of the association. After full-adjustment, an association remained (RRR [95% CI] at 23y = 2.00 [1.08-3.72]). Comorbidity risk related to ACEs differed by sex at 42.
CONCLUSION: Our study provides evidence on the link and potential mechanisms between ACEs and the co-occurrence of mental and physical diseases throughout the life-course. We suggest addressing ACEs in intervention strategies and public policies to go beyond single disease prevention.
PURPOSE:To produce Ca4P2O9 powder for a dental material having a high bulk density by mixing CaCO3 powder with CaHPO4 or Ca2P2O7 powder in a specified ratio, molding the powdery mixture under a high pressure, bringing the molded body into a reaction at a high temp. and carrying out crushing and classification. CONSTITUTION:CaCO3 powder is uniformly mixed with CaHPO4 powder in 1:1 molar ratio or with Ca2P2O7 powder in 2:1mol ratio. The powdery mixture is molded under >=0.1t/cm<2>, preferably about 1-25/cm<2> pressure. The molded body is burned at >=1,200 deg.C in the air for about 1-2hr and the burning reaction product is coarsely crushed, finely crushed and classified with a pneumatic classifier to obtain Ca4P2O9 powder contg. >=70wt% primary particles of 2-32mum particle size and having >=1.2, preferably >=about 1.4 bulk density. The powder is suitable for use as a dental material and can form a hardened body having high crushing resistance and a low breaking rate.
PURPOSE: To provide the composition which has good preservation stability, sufficient rheological characteristics such as good sticking to a toothbrush, low stress viscosity and low viscosity at high shear and the production, metering and dispensing of which can easily be performed. CONSTITUTION: This composition contains a grainy silicones polishing/cleaning agent which has a 50 to 900 m<2> /g specific surface area and is stably suspended in an aqueous liquid medium contg. substantially no polyol type humectant, by using as a suspending agent, polysaccharide gum such as xanthan gum or sodium carboxymethylate. The amount of the polysaccharide gum can be changed within the range of 0.25 to 2 wt.%, or preferably 0.3 to 1.5% and also, in order to attain required rheological characteristics, thickener silica is used together with the polysaccharide gum. At this time, the relative amounts between polysaccharide gum and thickener silica are selected so that the viscosity index value of the composition determined by the formula (20-S)/P (wherein S is a thickener silica concn. (%) and P is a polysaccharide gum concn. (%)) is 3 to 30, or preferably 3 to 15.
Background: Adolescent motherhood and malnutrition among children are significant challenges in Africa, but there is limited data on the impact of adolescent motherhood on their children's health and nutrition. This study assessed infant feeding practices, prevalence of adolescent motherhood, and malnutrition among infants in Mangu local government area (LGA). Methodology: A cross-sectional survey using multistage sampling was conducted. Validated questionnaires were used to collect socio-demographic data, and appropriate tools were used for anthropometric measurements. Data were compared with established standards. Descriptive statistical tools, chi square, Pearson correlation, and independent sample t-test were used for data analysis, with significance set at p < 0.05. Results: A total of 200 mothers completed the study. The majority of the infants (78.5%) were less than 6 months old, and 21.5% were 6-12 months old. Breastfeeding initiation within 1 hour was reported by 39% of mothers, while 38% practiced prelacteal feeding. Only 28.5% practiced exclusive breastfeeding, and all mothers breastfed their babies. The prevalence of adolescent motherhood was 37.5%. The prevalence of stunting, wasting, and underweight among infants were 29.5%, 12%, and 8.5%, respectively. Children of adolescent mothers had higher rates of severe stunting compared to children of mothers above 19 years of age. There were significant differences (p = 0.017 and p = 0.029) in stunting rates and weight-for-age indices between children of adolescent mothers and mothers above 19 years of age. Conclusion: Adolescent motherhood contributes to chronic malnutrition in children, and there is a high prevalence of malnutrition among infants in Mangu LGA, Plateau State.
When injected intravenously, Technetium Tc 99m Glucoheptonate is rapidly cleared from the blood. In patients with normal renal function, less than 15% of the initial activity remains in the blood after one hour. About 40% of the injected dose is excreted in the urine in one hour, while about 70% is excreted in 24 hours. In patients with renal disease, the blood clearance and urinary excretion of the radiopharmaceutical are delayed.

Up to 15% of the injected dose is retained in the kidneys. The renal retention is greater in the cortex than in the medulla. The radiopharmaceutical may be bound to the proximal convoluted tubules, which are located primarily in the renal cortex.

Technetium Tc 99m Glucoheptonate tends to accumulate in intracranial lesions that are associated with excessive neovascularity or an altered blood-brain barrier. The drug does not accumulate in the choroid plexus or salivary glands.
The invention belongs to the technical field of biology, and particularly discloses an antigen remarkably related to glioblastoma prognosis and application thereof, wherein the antigen comprises an antigen remarkably related to glioblastoma prognosis, and the antigen comprises at least one of LRP1, TCF12, DERL3, WIPI2 and TSHZ3 antigen genes. Application of at least one antigen of LRP1, TCF12, DERL3, WIPI2 and TSHZ3 antigen genes in preparation of glioblastoma multiforme therapeutic neoantigen cancer vaccine products. The LRP1 expression level detection agent is applied to preparation of a detection and analysis product for the prognosis effect of glioblastoma multiforme treatment. Application of LRP1 expression level detection agent in preparation of glioblastoma cell infiltration level detection product. The invention provides guidance for developing a therapeutic new antigen cancer vaccine for a patient with glioblastoma. LRP1 et al were demonstrated to be potential neoantigens for glioblastoma immunotherapeutic vaccines, with glioblastoma patients in cluster3 being more amenable to vaccination with this vaccine. Also provided are methods for screening populations suitable for vaccination with the corresponding antigen.
Abstract of the Disclosure The invention relates to polychromophoric heterocyclic ester compounds which have been found to be effective ultraviolet stabilizers.  The polychromophoric compositions of the present invention have the following structure:       wherein A is a group having the structure:       and .beta. is a group having the structure:       wherein X and Y are a carbon atom or a nitrogen atom; and Z is an oxygen atom, a sulfur atom, a nitrogen atom, a moiety consisting of a nitrogen atom and a hydrogen atom or a stituted or unsubstitued lower alkyl group containing 1 to 12 carbon atoms.           The invention also relates to ultraviolet degradable organic compositions containing a stabilizing amount of these poly-chromophoric heterocyclic ester compositions to prevent sucf segrada-tion.  These stabilizers are effective in the presence of other additives commonly employed in polymeric compositions including, for example, pigments, colorants, fillers, reinforcing agents and the like.  These ultraviolet stabilizers may also be incorporated into the organic compositions in the polymer melt or dissolved in the polyemer dope, coated on the exterior of the molded article, film or extuded fiber.     - i -
FIELD: medicine.SUBSTANCE: method for weight reduction involves a complex food formulation (CFF) for weight reduction by 4-6 kg for the one-month daily consumption. The CFF is placed into a package, storage, transportation kit of food for weight reduction. The CFF for weight reduction is provided for 24 days, including breakfasts, lunches and dinners, and 4 fasting days at one fasting day a week. Each food item is packed and marked with a specific colour. The food items are selected to have a low glycemic index, a low fat percentage and a low salt percentage. For 24 days, the patient takes 4 meals - breakfast, lunch, sweet course and dinner, besides the patient takes approximately 2 litres of still sugarless, unsalted water for each day. In addition, for each of twenty-four days, one glass of sugarless plain tea or coffee a day, one glass of milk or kefir 3.5% or less with breakfast, lunch or dinner, green salad or vegetable salad are allowed. Sweet course can include no more than one big fruit or no more than two smaller fruit, or no more than a hundred and fifty gram of fresh berries a day. A caloric value of the dishes is maintained so that the daily caloric value is no more than 800 kcal. Each fasting day implies drinking approximately 8-10 glasses of still sugarless, unsalted water. The fasting day involves drinking water and eating one pack of undercooked and unsalted rice of four prescribed for a day alternatively. An amount of each single meal on any day shall not exceed on glass or 250 gram. Lunches, dinners, a portion of breakfasts are transported and stored frozen; other portion of breakfasts are prepared dry. All the food items are placed into two package, storage, transportation kits of food for weight reduction. Each complex rests on a foam plastic thermal box. The food items are laid in lines interleaved with a paper gasket. An upper paper gasket is covered with ice packs; the thermal box is capped and placed into a card corrugated box. The food items required no pre-freezing are placed in the thermal box from above. The corrugated box is covered; a leaflet containing food item names and user's information is attached on an outer side of the corrugated box to be delivered to the consumer. To ensure a month course of weight reduction, each consumer shall use the content of both packed corrugated boxes completely.EFFECT: invention enables reducing the length of weight reduction to 4-6 kg a month and maintaining the achieved weight for a long period of time after using the course of weight reduction.3 cl, 4 tbl
The invention comprises compounds of the general formula <FORM:0888690/IV (b)/1> where R1 represents a monoalkylamino or dialkylamino group containing at least one alkyl group containing at least three carbon atoms, or an alkyleneamino group in which the alkylene chain may be interrupted by oxygen or nitrogen atoms and R2 represents a hydrogen atom or has the meaning given for R1) and acid addition salts thereof, and pharmaceutical compositions (see Group VI) containing these compounds; and the preparation thereof by reacting together an amine HR1 and a 1-isopropyl-pyrazolo [3 : 4] pyrimidine substituted at the 4-position and, if desired, also at the 6-position by a substituent capable of being replaced by the radical R1. The products have pharmacological properties, primarily a coronary dilation effect.  1 - Isopropyl - 4 - methylmercapto - pyrazolo [3,4-d] pyrimidine is prepared by methylating the corresponding mercaptan.  1 - Isopropyl - 4 - mercapto - pyrazolo [3 :4 - d] pyrimidine is prepared by treating 1-isopropyl-4-chloro-pyrazolo [3 : 4-d]pyrimidine with thiourea. 1-Isopropyl-4 : 6-dihydroxy-pyrazolo [3 : 4-d] pyrimidine is prepared by reacting 2-isopropyl-3-amino-4-carbamyl-pyrazole with urea. Specifications 854,632 and 877,130 also are referred to.ALSO:Pharmaceutical preparations, having coronary dilation, analgesic, antirheumatic and diuretic effects, comprise, in association with a carrier suitable for enteral, parenteral or local administration, compounds of the general formula <FORM:0888690/VI/1> (where R1 represents a monoalkylamino or dialkylamino group containing at least one alkyl group containing at least 3 carbon atoms, or an alkyleneamino group in which the alkylene chain may be interrupted by oxygen or nitrogen atoms, and R2 represents a hydrogen atom or a group as defined for R1) or their physiologically tolerated acid addition salts (e.g. hydrohalides, sulphates, phosphates, nitrates, perchlorates, ascorbates, or aliphatic, alicyclic, aromatic or heterocyclic carboxylates or sulphonates).  They may take the form of tablets, dragees, solutions, suspensions or emulsions, and may be sterilized and/or may contain preserving, stabilizing, wetting or emulsifying agents, or additional therapeutically valuable substances.  Specifications 854,632 and 877,130 also are referred to.
Participants with no detectable hiatal hernia will be randomized to either Group 2 or 3. Group 2 participants will be treated to the national practice patterns of complete dissection of the curvature of the stomach without dissection of the crura.
OBJECTIVES: With smartphones and wearable devices becoming ubiquitous, they offer an opportunity for large-scale voice sampling. This systematic review explores the application of deep learning models for the automated analysis of voice samples to detect vocal cord pathologies.
METHODS: We conducted a systematic literature review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. We searched MEDLINE and Embase databases for original publications on deep learning applications for diagnosing vocal cord pathologies between 2002 and 2022. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2).
RESULTS: Out of the 14 studies that met the inclusion criteria, data from a total of 3037 patients were analyzed. All studies were retrospective. Deep learning applications targeted Reinke's edema, nodules, polyps, cysts, unilateral cord paralysis, and vocal fold cancer detection. Most pathologies had detection accuracy above 90%. Thirteen studies (93%) exhibited a high risk of bias and concerns about applicability.
CONCLUSIONS: Technology holds promise for enhancing the screening and diagnosis of vocal cord pathologies. While current research is limited, the presented studies offer proof of concept for developing larger-scale solutions.
Subjects will be transitioned to JZP-258 based on their treatment status at study entry. All subjects will begin JZP-258 treatment at the beginning of this period and continue through Week 12. They will be treated with JZP-258 alone for the final two weeks of this 12-week period. Once the JZP-258 dose has been optimized per the Investigator's judgment, these subjects may enter the 2-week Stable-Dose Period with that dose. Subjects are eligible to enter the Double-Blind Randomized-Withdrawal Period if the dose of JZP-258 remains unchanged during the Stable-Dose Period and, in the judgment of the Investigator, no clinically significant worsening in narcolepsy symptoms or clinically significant adverse events due to JZP-258 treatment have occurred. Subjects will return for a Safety Follow-up visit 2 weeks after the Double-Blind Randomized-Withdrawal Period. Subjects who complete the double-blind treatment period during the Main Study are eligible to enter a 24-week Open-Label Extension. During this period subjects will receive open label JZP-258. Subjects will return for a Safety Follow-up visit 2 weeks after the Open-Label Extension Period.
Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
For SG-uncut JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
BACKGROUND & AIMS: It has been revealed good nutritional status and no physical frailty, which are modifiable lifestyle factors, are linked to less cognitive decline and a lower risk of Alzheimer's disease (AD). We aimed to investigate the associations between nutritional status and physical frailty and plasma AD biomarkers, especially the Tau-associated biomarkers in older cognitively unimpaired (CU) adults with higher β-amyloid (Aβ) burden.
METHODS: The nutritional status and physical frailty were assessed via Mini-Nutritional Assessment Short-Form (MNA-SF) and Fried frailty index. The participants underwent the examination of plasma AD biomarkers and 18F-florbetapir PET scan as well as 18F-MK6240 PET in the validation cohort. Correlation and multiple linear regression analyses were used to investigate the associations between nutritional status and frailty and AD biomarkers.
RESULTS: Two cohorts were included in our study. A total of 129 participants with Aβ-PET positive were enrolled in the development cohort. Multiple linear regression analysis showed MNA-SF scores, normal nutritional status, Fried frailty index scores, frailty and some domains of frailty including weight loss, maximal grip strength and exhaustion were associated with plasma p-Tau-181. Furthermore, weight loss, Fried frailty index scores and frailty were associated with higher Aβ-PET standard uptake value ratio. We further performed subgroup analyses stratified by age, sex and apolipoprotein E ε4 genotype to investigate the beneficial characteristics of nutrition and frailty in the special subgroups. Validation cohort contained 38 Aβ-PET positive participants. MNA-SF scores, normal nutritional status, Fried frailty index scores and frailty were associated with Tau burden evaluated by 18F-MK6240 PET Braak-like stages.
CONCLUSIONS: Our data indicates that normal nutritional status and no physical frailty may be associated with expected trend of plasma AD biomarkers, especially less Tau pathology in older CU adults with Aβ deposition. Adjusting to these characteristics of nutrition and physical frailty may help reduce the risk of AD development.
One of the fluoroquinolone antibiotics, levofloxacin (LEV), is used to treat a variety of illnesses leading to oxidative stress and cellular damage. Peel from Punica granatum is a waste product abundant in phytochemicals with various biological activities. This study aimed to evaluate P. granatum peel extract's (PGPE) potential to mitigate oxidative stress, inflammation, apoptosis, and liver damage caused by LEV. There were four groups of rats: control, PGPE, LEV, and PGPE + LEV, respectively, and they were orally administered their daily treatments for 2 weeks. Results revealed that PGPE has a large number of phytochemical components with high antioxidant activity. PGPE intake alone enhanced the antioxidant status and decreased oxidative stress. On the other hand, pretreatment of the LEV group with PGPE restored oxidative stress, antioxidant enzymes, glutathione content, liver function biomarkers, and hematological parameters. Also, normalization of gene expressions (cyclooxygenase-2, transforming growth factor-beta1, caspase-3, heme oxygenase-1, B cell lymphoma-2, interleukin [IL]-10, and IL-1) and improvement in liver architecture, and immunohistochemical alpha-smooth muscle actin, were seen in comparison to the LEV group. Conclusively, PGPE exhibits strong anti-inflammatory, antiapoptotic, and antioxidant properties that shield rat liver from the damaging effects of LEV and offer a fresh viewpoint on the application of fruit waste products.